EU Fails to Address Smoking with Global Health Strategy

Dec.06.2022
EU Fails to Address Smoking with Global Health Strategy
The EU's global health strategy ignored e-cigarettes, drawing criticism from experts and consumer groups. A new tax plan raises concerns.

On December 5th, the European Commission (EC) announced its "Global Health Strategy" which aims to prioritize tackling the root causes of poor health. However, the strategy failed to address the issue of smoking through means of reducing tobacco harm.


The director of the World Vapers' Alliance (WVA), Michael Landl, has emphasized that the European Union (EU) has disregarded the science behind electronic cigarettes.


He stated: "The European Commission has once again ignored the voices of science and consumers. Reducing tobacco harm must be a key element of all EU health policies. 700,000 people die each year from smoking, while the Commission fights against less harmful alternatives. Science is clear that the harm of electronic cigarettes is much lower than smoking and they are one of the most effective smoking cessation aids. Consumers are demanding that the Commission finally accept this reality.


Meanwhile, in light of potential backlash against European Union efforts to reduce smoking rates, the EU has leaked a draft plan to increase taxes on electronic cigarette products, causing concern among the public. Experts in tobacco harm reduction and consumer groups have emphasized that such a tax would not only have adverse effects on public health, but could also create a large-scale new black market for electronic cigarette products.


The committee claims that increasing taxes will improve public health, but the facts say the opposite. Ordinary smokers trying to quit must be able to afford a less harmful substitute such as e-cigarettes. If the committee wants to mitigate the burden of smoking on public health, they must make e-cigarettes more affordable and accessible, not less," said Michael Landl, director of the World Vapers' Alliance (WVA).


2FIRSTS will continue to cover this topic, with updates available on the '2FIRSTSAPP.' Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10
Austintown PTA hosts “Live Vape Free” town hall to discuss teen vaping risks and prevention
Austintown PTA hosts “Live Vape Free” town hall to discuss teen vaping risks and prevention
The Austintown Parent Teacher Association hosted a “Live Vape Free” town hall to discuss the dangers of vaping devices among middle and high schoolers, the report said. The event was funded by the National PTA Vape-Free Futures Challenge Grant, provided in collaboration with the Campaign for Tobacco-Free Kids, and Austintown was one of seven PTAs nationwide to receive it.
Feb.27 by 2FIRSTS.ai
NYC makers turn discarded disposable vapes into “Vape Synth” mini digital instruments
NYC makers turn discarded disposable vapes into “Vape Synth” mini digital instruments
The report says disposable vapes are sold at more than 11 million units per month and often end up in landfills after flavored nicotine juice runs out, along with lithium-ion batteries, microcontrollers, and LEDs, increasing the risk of waste fires. A New York City maker trio known as Paper Bag Team has built “Vape Synth” by cracking open spent Elf Bar cartridges—specifically the EB BC5000—and hacking them into tiny digital instruments.
Feb.12 by 2FIRSTS.ai
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
The FDA has added Glas products to its authorized electronic nicotine delivery systems (ENDS) list, granting Marketing Granted Orders (MGOs) to the Glas G DEVICE and a BLONDE TOBACCO pod. The decision expands the number of FDA-authorized ENDS products to 41, marking the first new authorization since Juul’s approvals in July 2025. However, widely anticipated non-tobacco flavored products were not approved.
Mar.13
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
Korea Disease Control and Prevention Agency’s Youth Health Panel Survey (2025) Final Results Report says key adolescent health indicators worsen as students move up grade levels. By 11th grade, lifetime tobacco experience rose to 9.59%. Among 11th-grade girls, current use of liquid e-cigarettes (1.54%) surpassed conventional cigarettes (1.33%) for the first time.
Feb.10 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11